Company / Net Income
Corvus Pharmaceuticals, Inc. Net Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$62.3M
FY2024
5-year range
-$62.3M / -$6.0M
FY2020-FY2024
Trend
-130.5%
vs FY2023
Sector context
#86 of 214
Health Care
What the data says
At -$62M, Corvus Pharmaceuticals, Inc.'s net income ranks #86 of 214 in the Health Care sector. Net Income has fluctuated over the past 10 years, ranging from -$62M in FY2024 to -$6M in FY2020.
Based on SEC 10-K filings.
-$62M in FY2024.
Declined from -$41M to -$62M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#86 of 214 in Health CareTop 40% of 214This company -$62.3M Sector average $443.1M
▼
-114.1% below sector average
Key checks
Key Insights
- In FY2024, net income decreased 130.5% year-over-year.
- Ranks #86 out of 214 companies in the Health Care sector.
- Peak net income was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$62.3M | -130.5% |
| FY2023 | -$27.0M | +34.6% |
| FY2022 | -$41.3M | +4.5% |
| FY2021 | -$43.2M | -621.3% |
| FY2020 | -$6.0M | +87.2% |
| FY2019 | -$46.7M | +0.6% |
| FY2018 | -$46.9M | +15.7% |
| FY2017 | -$55.7M | -53.0% |
| FY2016 | -$36.4M | -16.1% |
| FY2015 | -$31.3M | -19362.7% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026